Ironwood Pharmaceuticals reported $33.22M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Almirall EUR 71.55M 41.32M Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amarin USD -2.26M 564K Dec/2025
Ardelyx USD -12.42M 20.37M Jun/2026
Astellas Pharma JPY 132.59B 52.76B Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Charles River Laboratories USD 202.64M 82.75M Sep/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Emergent BioSolutions USD -218M 69.9M Jun/2023
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
MacroGenics USD -13.85M 19.59M Jun/2026
Moderna USD 130M 945M Sep/2026
Myriad Genetics USD -3M 20.3M Dec/2025
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Takeda JPY 205.32B 3.9B Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024